These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies. Sharma A; Jain S; Gupta R; Guleria S; Agarwal S; Dinda A Indian J Pathol Microbiol; 2010; 53(4):651-7. PubMed ID: 21045386 [TBL] [Abstract][Full Text] [Related]
3. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts. Liptak P; Ivanyi B Nat Clin Pract Nephrol; 2006 Jul; 2(7):398-404; quiz following 404. PubMed ID: 16932468 [TBL] [Abstract][Full Text] [Related]
4. The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors. Coates PT; Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S85-7. PubMed ID: 17316286 [No Abstract] [Full Text] [Related]
5. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. Metalidis C; Lerut E; Naesens M; Kuypers DR Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031 [TBL] [Abstract][Full Text] [Related]
11. Dual RAS therapy not on target, but fully alive. Lambers Heerspink HJ; de Zeeuw D Nephron Clin Pract; 2010; 116(2):c137-42. PubMed ID: 20516713 [TBL] [Abstract][Full Text] [Related]
12. Differential expression of tissue factor (TF) in calcineurin inhibitor-induced nephrotoxicity and rejection--implications for development of a possible diagnostic marker. Osterholm C; Veress B; Simanaitis M; Hedner U; Ekberg H Transpl Immunol; 2005 Dec; 15(2):165-72. PubMed ID: 16412961 [TBL] [Abstract][Full Text] [Related]
13. The CARI guidelines. Calcineurin inhibitors in renal transplantation: pregnancy, lactation and calcineurin inhibitors. Grimer M; Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S98-S105. PubMed ID: 17316288 [No Abstract] [Full Text] [Related]
14. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. Gallon L; Akalin E; Lynch P; Rothberg L; Parker M; Schiano T; Abecassis M; Murphy B Transplantation; 2006 Feb; 81(3):463-8. PubMed ID: 16477235 [TBL] [Abstract][Full Text] [Related]
15. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Ahmed AK; Kamath NS; El Kossi M; El Nahas AM Nephrol Dial Transplant; 2010 Dec; 25(12):3977-82. PubMed ID: 19820248 [TBL] [Abstract][Full Text] [Related]
16. The CARI guidelines. Calcineurin inhibitors in renal transplantation: adverse effects. Jose M; Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S66-74. PubMed ID: 17316284 [No Abstract] [Full Text] [Related]
18. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Hesselink DA; Bouamar R; van Gelder T Ther Drug Monit; 2010 Aug; 32(4):387-93. PubMed ID: 20571464 [TBL] [Abstract][Full Text] [Related]
19. Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. Prókai Á; Csohány R; Sziksz E; Pap D; Balicza-Himer L; Boros S; Magda B; Vannay Á; Kis-Petik K; Fekete A; Peti-Peterdi J; Szabó AJ Transplantation; 2016 Feb; 100(2):325-333. PubMed ID: 26502369 [TBL] [Abstract][Full Text] [Related]